The cost-effectiveness of medication, laser trabeculoplasty, and trabeculectomy for treatment of open-angle glaucoma in South Korea. Issue 2 (January 2019)

• Record Type: Journal Article
• Authors: Choi, Jin A.; Song, Lina D.; Choi, Seulggie; Park, Sang Min; Kwon, Jin Woo; Jee, Donghyun
• Other Names: Desapriya. Ediriweera section editor.
• Is Part Of: Medicine. Volume 98:Issue 2(2019)
• Publication Date: 2019-01
• Subjects: cost-effectiveness -- glaucoma medication -- laser -- life-years -- open-angle glaucoma -- open-angle glaucoma management -- quality-adjusted -- trabeculectomy -- trabeculoplasty; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000014026
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Objectives: Open-angle glaucoma (OAG) imposes high disease burden in South Korea. Although various effective interventions are available to manage the progression of OAG, there is limited data on the cost-effectiveness of these treatment strategies in South Korea. Methods: Using a Markov cohort model, we evaluated the cost-effectiveness of 3 major treatment strategies (medication, laser trabeculoplasty, and trabeculectomy) for South Korean patients with OAG. We projected a 25-year time horizon to study a hypothetical cohort of 10, 000 patients of age 40 with mild OAG. The outcome measures were quality-adjusted life-years (QALYs) gained, cost from the societal perspective, and the incremental cost-effectiveness ratio (ICER) of medication, laser trabeculoplasty, and trabeculectomy. Interventions were evaluated at a willingness-to-pay (WTP) threshold of 30, 000, 000 KRW ($29, 152) per QALY gained. Deterministic and probabilistic sensitivity analyses were conducted to address the model uncertainty. Results: The mean costs for medication, laser trabeculoplasty, and trabeculectomy were 29, 661, 740 KRW, 17, 34, 1342 KRW, and 22, 275, 438 KRW, respectively. The mean QALYs gained were 15.7, 15.3, and 14.8 for medication, laser trabeculoplasty, and trabeculectomy, respectively. Surgery was strongly dominated because it generated fewer expected QALYs but incurred greater expected cost than laser. The ICER was 30, 885, 179 KRW per QALY for medication versus laser trabeculoplasty. Laser was cost-effective, however, at a lower WTP threshold of 21, 000, 000 KRW per QALY gained or below. The results were most sensitive to the progression rates from mild to moderate glaucoma under laser treatment. Conclusion: Under the WTP threshold of 30, 000, 000 KRW per QALY, medication was cost-effective compared with laser trabeculoplasty and trabeculectomy for treating mild OAG in South Korean population. Laser, however, can be a cost-effective alternative in more resource-limited settings.